These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Greiner J; Ono Y; Hofmann S; Schmitt A; Mehring E; Götz M; Guillaume P; Döhner K; Mytilineos J; Döhner H; Schmitt M Blood; 2012 Aug; 120(6):1282-9. PubMed ID: 22592607 [TBL] [Abstract][Full Text] [Related]
3. HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid Leukemia. Narayan R; Niroula A; Wang T; Kuxhausen M; He M; Meyer E; Chen YB; Bhatt VR; Beitinjaneh A; Nishihori T; Sharma A; Brown VI; Kamoun M; Diaz MA; Abid MB; Askar M; Kanakry CG; Gragert L; Bolon YT; Marsh SGE; Gadalla SM; Paczesny S; Spellman S; Lee SJ Transplant Cell Ther; 2023 Jul; 29(7):452.e1-452.e11. PubMed ID: 36997024 [TBL] [Abstract][Full Text] [Related]
4. Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. Forghieri F; Riva G; Lagreca I; Barozzi P; Vallerini D; Morselli M; Paolini A; Bresciani P; Colaci E; Maccaferri M; Gilioli A; Nasillo V; Messerotti A; Pioli V; Arletti L; Giusti D; Bettelli F; Celli M; Donatelli F; Corradini G; Basso S; Gurrado A; Cellini M; Trenti T; Marasca R; Narni F; Martelli MP; Falini B; Potenza L; Luppi M; Comoli P Oncotarget; 2019 Jan; 10(8):869-882. PubMed ID: 30783516 [TBL] [Abstract][Full Text] [Related]
5. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Dong H; Ham JD; Hu G; Xie G; Vergara J; Liang Y; Ali A; Tarannum M; Donner H; Baginska J; Abdulhamid Y; Dinh K; Soiffer RJ; Ritz J; Glimcher LH; Chen J; Romee R Proc Natl Acad Sci U S A; 2022 Jun; 119(25):e2122379119. PubMed ID: 35696582 [TBL] [Abstract][Full Text] [Related]
6. Minimal/Measurable Residual Disease Monitoring in Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199 [TBL] [Abstract][Full Text] [Related]
7. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. van der Lee DI; Reijmers RM; Honders MW; Hagedoorn RS; de Jong RC; Kester MG; van der Steen DM; de Ru AH; Kweekel C; Bijen HM; Jedema I; Veelken H; van Veelen PA; Heemskerk MH; Falkenburg JHF; Griffioen M J Clin Invest; 2019 Feb; 129(2):774-785. PubMed ID: 30640174 [TBL] [Abstract][Full Text] [Related]
8. Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1 De Cicco M; Lagreca I; Basso S; Barozzi P; Muscianisi S; Bianco A; Riva G; Di Vincenzo S; Pulvirenti C; Sapuppo D; Siciliano M; Rosti V; Candoni A; Zecca M; Forghieri F; Luppi M; Comoli P Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345068 [TBL] [Abstract][Full Text] [Related]
9. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446 [TBL] [Abstract][Full Text] [Related]
10. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy? Roerden M; Nelde A; Walz JS Front Immunol; 2019; 10():3004. PubMed ID: 31921218 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501 [TBL] [Abstract][Full Text] [Related]
12. Discovery of U2AF1 neoantigens in myeloid neoplasms. Biernacki MA; Lok J; Black RG; Foster KA; Cummings C; Woodward KB; Monahan T; Oehler VG; Stirewalt DL; Wu D; Rongvaux A; Deeg HJ; Bleakley M J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164756 [TBL] [Abstract][Full Text] [Related]
13. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1. Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521 [TBL] [Abstract][Full Text] [Related]
14. Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor. Nemeckova S; Alexova-Zurkova K; Hainz P; Krystofova J; Mackova J; Roubalova K; Stastna-Markova M; Vrana M; Vydra J Curr Oncol; 2022 Apr; 29(5):2928-2934. PubMed ID: 35621629 [TBL] [Abstract][Full Text] [Related]
15. Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody. Greiner J; Goetz M; Schuler PJ; Bulach C; Hofmann S; Schrezenmeier H; Dӧhner H; Schneider V; Guinn BA Br J Haematol; 2022 Sep; 198(5):866-874. PubMed ID: 35799423 [TBL] [Abstract][Full Text] [Related]
16. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations. Zheng WS; Hu YL; Guan LX; Peng B; Wang SY Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943 [TBL] [Abstract][Full Text] [Related]
17. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. El Hussein S; DiNardo CD; Takahashi K; Khoury JD; Fang H; Furudate K; Lyapichev KA; Garces S; Kanagal-Shamanna R; Ok CY; Patel KP; Routbort MJ; Ravandi F; Medeiros LJ; Wang SA; Loghavi S Bone Marrow Transplant; 2022 Mar; 57(3):370-376. PubMed ID: 34992253 [TBL] [Abstract][Full Text] [Related]
18. Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation. Hofmann S; Götz M; Schneider V; Guillaume P; Bunjes D; Döhner H; Wiesneth M; Greiner J J Clin Oncol; 2013 Jan; 31(3):e44-7. PubMed ID: 23248243 [No Abstract] [Full Text] [Related]
19. Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. Narayan R; Olsson N; Wagar LE; Medeiros BC; Meyer E; Czerwinski D; Khodadoust MS; Zhang L; Schultz L; Davis MM; Elias JE; Levy R PLoS One; 2019; 14(7):e0219547. PubMed ID: 31291378 [TBL] [Abstract][Full Text] [Related]